U.S. markets closed

ENDRA Life Sciences to Participate at Upcoming Investor Conferences

The Medical Alley Innovation Summit Minneapolis 2017 on September 18 & the Dougherty & Company Institutional Investor Conference on September 19

ANN ARBOR, MI / ACCESSWIRE / September 7, 2017 / ENDRA Life Sciences Inc. ("ENDRA") (NDRA), a developer of enhanced ultrasound technologies, has been invited to participate at two upcoming conferences in September 2017.

The Medical Alley Innovation Summit Minneapolis 2017 is being held on September 18-19, 2017 at the Marriott City Center in Minneapolis. ENDRA CEO, Francois Michelon, and CFO, David Wells, are scheduled to present on Monday, September 18 at 4:55 p.m. Central time with one-on-one meetings held throughout the conference. For additional information or to schedule a one-on-one meeting with ENDRA management, please email your request to NDRA@mzgroup.us or call Chris Tyson at (949) 491-8235.

The Dougherty and Company Institutional Investor Conference is being held on September 19, 2017 at the Millennium Hotel in Minneapolis. ENDRA CEO, Francois Michelon, and CFO, David Wells, will hold one-on-one and small group meetings with institutional investors throughout the day. To schedule a meeting, please contact your Dougherty and Company representative. You may also email your meeting request to NDRA@mzgroup.us or call Chris Tyson at (949) 491-8235.

About the Medical Alley Innovation Summit Minneapolis 2017

The Medical Alley Innovation Summit provides a forum for innovative emerging medical technology companies seeking investment, joint venture or other relationships to gain exposure to venture capital, investment bankers, institutional investment funds and large medical device companies for the purpose of potential investment and/or strategic partnership. It is organized as a two-day business partnering and networking event, featuring 40 pre-screened start-up medical technology companies that will deliver 10-minute presentations, followed by meetings in private breakout rooms. The Summit will also feature thought-leading guest speakers, and plenary and panel sessions, all providing candid insight on topics of utmost importance to all stakeholders in the rapidly evolving global device marketplace. In attendance, will be 350+ of the top medical device VCs and senior business development executives from Minnesota's vibrant Medical Alley area, as well as many other parts of the U.S., Europe, Asia and around the world, in addition to management teams from many of the most promising start-ups in the device space. For more information, please click here.

About the Dougherty & Company Institutional Investor Conference

Founded in 1977, Dougherty & Company is a full-service financial services firm that delivers a wide array of products and solutions to both institutions and individuals nationwide. Headquartered in Minneapolis, they have extensive experience in public finance where Dougherty has originated more than $48 billion in financings as managing/co-managing underwriter, placement agent and financial advisor. Dougherty has particular expertise in the Midwest and been a leader in the municipal fixed income industry since inception. Leveraging its research experience across multiple sectors in small-cap companies, Dougherty created a full-day conference at the Millennium Hotel in Minneapolis that includes hosted one-on-one and small group meetings with the management teams of some of their best ideas. For more information, please click here.

About ENDRA Life Sciences Inc.

ENDRA Life Sciences Inc. ("ENDRA") (NDRA) is a developer of enhanced ultrasound technologies. ENDRA's Photo-Acoustic Nexus-128 system is currently used by leading global medical researchers to screen and modify disease models with high image quality and volume scanning speed. ENDRA's next generation Thermo-Acoustic Enhanced UltraSound ("TAEUS") will enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only on CT & MRI -- at a fraction of the cost, and at the point-of-care. ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally. ENDRA's goal is to bring new capabilities to ultrasound -- thereby broadening access to better healthcare. For more information, please visit www.endrainc.com.

Company Contact:

David Wells
Chief Financial Officer
(734) 997-0464
investors@endrainc.com
www.endrainc.com

Media & Investor Relations Contact:

MZ North America
Chris Tyson
Managing Director
(949) 491-8235
NDRA@mzgroup.us
www.mzgroup.us

SOURCE: ENDRA Life Sciences Inc.